Celerion collaborates with both emerging and established pharmaceutical and biotechnology companies to test new drug candidates in humans for the first time and help with rapid but safe progression of these agents to Clinical Proof-of-Concept (CPoC). CPoC is reached when sufficient evidence is collected to demonstrate the drug is working as planned, and to stimulate further investment in the drug’s clinical development. Reaching this critical milestone usually involves administration of the therapy to normal subjects as well as patients in the target disease population and often involves the deployment of specific biomarkers of drug effect.
Celerion is able to leverage its clinic facilities, biomarker analysis capabilities, PK/PD analysis skills and program planning experience to generate “fast-to-patient” strategies that minimize the time to key go/no-go decisions. We have actively invested in new technologies to enrich data collection and analysis and to expedite data delivery to our clients.
By tapping Celerion’s experience in managing more than 6000 clinical research studies in more than 30 countries, we can find the right subjects for these important studies. Whether the new treatment is for an oncology indication, autoimmune disease, diabetes, obesity, hepatic or renal disease, respiratory ailments, infections or is a vaccine, Celerion provides access to difficult to recruit patient populations. Celerion’s European team has experience in personalized medicine in the form of autologous cell-based therapies.